Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 72.95 INR
Change Today 0.00 / 0.00%
Volume 0.0
RLPH On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

relish pharmaceuticals ltd (RLPH) Snapshot

Open
66.05
Previous Close
72.95
Day High
72.95
Day Low
66.05
52 Week High
04/24/15 - 113.68
52 Week Low
08/27/14 - 1.57
Market Cap
114.2M
Average Volume 10 Days
32.3
EPS TTM
0.08
Shares Outstanding
1.6M
EX-Date
--
P/E TM
935.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for RELISH PHARMACEUTICALS LTD (RLPH)

Related News

No related news articles were found.

relish pharmaceuticals ltd (RLPH) Related Businessweek News

No Related Businessweek News Found

relish pharmaceuticals ltd (RLPH) Details

Relish Pharmaceuticals Limited manufactures, exports, and markets various drugs and dosage forms in India and internationally. The company’s product portfolio includes antibiotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products. Relish Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.

Founded in 1993

relish pharmaceuticals ltd (RLPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

relish pharmaceuticals ltd (RLPH) Key Developments

Relish Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

Relish Pharmaceuticals Limited reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, net sales /income from operations was INR 3.942 million compared to INR 16.192 million a year ago. Loss from operations before other income finance cost and exceptional items was INR 1.315 million compared to profit from operations before other income finance cost and exceptional items of INR 6.185 million a year ago. Profit from ordinary activities before tax was INR 2.825 million against INR 7.844 million a year ago. Net profit was INR 1.463 million or INR 0.09 per basic and diluted share before and after extraordinary items compared to net profit of INR 7.844 million or INR 0.50 per basic and diluted share before and after extraordinary items a year ago. For the full year, net sales /income from operations was INR 26.378 million compared to INR 44.078 million a year ago. Loss from operations before other income finance cost and exceptional items was INR 6.944 million compared to INR 9.300 million a year ago. Profit from ordinary activities before tax was INR 2.586 million against loss from ordinary activities before tax of INR 6.968 million a year ago. Net profit was INR 1.224 million or INR 0.08 per basic and diluted share before and after extraordinary items compared to net loss of INR 7.625 million or INR 0.49 per basic and diluted share before and after extraordinary items a year ago.

Relish Pharmaceuticals Limited, Board Meeting, May 16, 2015

Relish Pharmaceuticals Limited, Board Meeting, May 16, 2015. Agenda: To report audited standalone earnings results for the fourth quarter and full year ended March 31, 2015.

Relish Pharmaceuticals Limited Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Relish Pharmaceuticals Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales of INR 3.841 million against INR 11.770 million a year ago. Loss from operations before other income, finance costs and exceptional items of INR 1.970 million against loss from operations before other income, finance costs and exceptional items of INR 3.135 million a year ago. Loss from ordinary activities before tax was INR 0.931 million against loss from ordinary activities before tax of INR 3.135 million a year ago. Net loss for the period was INR 0.931 million against net loss for the period of INR 3.135 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.06 against basic and diluted loss per share before and after extraordinary items of INR 0.03 a year ago.   For the nine months period, the company reported net sales of INR 22.436 million against INR 28.740 million a year ago. Loss from operations before other income, finance costs and exceptional items of INR 5.629 million against loss from operations before other income, finance costs and exceptional items of INR 14.515 million a year ago. Loss from ordinary activities before tax was INR 0.239 million against loss from ordinary activities before tax of INR 14.515 million a year ago. Net loss for the period was INR 0.239 million against net loss for the period of INR 14.515 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.02 against basic and diluted loss per share before and after extraordinary items of INR 0.14 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RLPH:IN 72.95 INR 0.00

RLPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RLPH.
View Industry Companies
 

Industry Analysis

RLPH

Industry Average

Valuation RLPH Industry Range
Price/Earnings 100.0x
Price/Sales 44.2x
Price/Book 8.4x
Price/Cash Flow 15.5x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RELISH PHARMACEUTICALS LTD, please visit www.relishpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.